Skip to main content

Table 1 Mortality during treatment

From: Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

Transplanted cells

Treatment

Day of treatment (spleen size)

1.5 × 106 Bcr-Abl BM

vehicle

day 8 (380 mg), day 12 (n.a.)

1.5 × 106 Bcr-Abl BM

vehicle + IgG

day 9 (274 mg), day 12 (410 mg), day 13 (77 mg)

1.5 × 106 Bcr-Abl BM

nilotinib

none

1.5 × 106 Bcr-Abl BM

nilotinib + infliximab

day 7 (91 mg), day 9 (108 mg)

1.5 × 106 wt BM

vehicle

none